October 28, 2020
The first patient has been enrolled in a global PIII study designed to evaluate Eisai’s resurrected investigational TLR4 antagonist eritoran and Amgen’s PDE4 inhibitor apremilast, known as Otezla, as potential therapeutic agents to treat patients with COVID-19. The two companies...read more